Survival of patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation

• Published in: European journal of radiology 2018-05, Vol.102, p.138-145
• Main Authors: Vogl, Thomas J., Lahrsow, Maximilian, Albrecht, Moritz H., Hammerstingl, Renate, Thompson, Zachary M., Gruber-Rouh, Tatjana
• Format: Article
• Language: English
• Subjects: Ablation Techniques - methods; Ablation Techniques - mortality; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Camptothecin - analogs & derivatives; Chemoembolization, Therapeutic - methods; Chemoembolization, Therapeutic - mortality; Cisplatin - administration & dosage; Colonic Neoplasms - mortality; Colorectal cancer (CRC); Colorectal cancer liver metastases (CRLM); Colorectal Neoplasms - mortality; Conventional transarterial chemoembolization (cTACE); Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Disease-Free Survival; Ethiodized Oil - administration & dosage; Female; Humans; Hyperthermia, Induced - methods; Hyperthermia, Induced - mortality; Laser Therapy - methods; Laser Therapy - mortality; Laser-induced thermotherapy (LITT); Liver Neoplasms - mortality; Liver Neoplasms - secondary; Liver Neoplasms - therapy; Male; Microwave ablation (MWA); Microwaves - therapeutic use; Middle Aged; Mitomycin - administration & dosage; Neoadjuvant Therapy - methods; Neoadjuvant Therapy - mortality; Palliative Care - methods; Percutaneous thermal ablation; Prognosis; Rectal Neoplasms - mortality; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult
• ISSN: 0720-048X; 1872-7727
• DOI: 10.1016/j.ejrad.2018.03.015

•cTACE is an effective treatment option in patients with advanced non-resectable CRLM.•cTACE followed by percutaneous thermal ablation increases OS and PFS.•Extrahepatic metastases are a prognostic factor in the OS and PFS in cTACE therapy.•Hepatic tumor burden influences OS and PFS in neoadjuvant cTACE prior to ablation.•A triple combination of chemotherapeutics improves response to cTACE. To determine overall (OS) and progression-free survival (PFS) for cTACE alone and in combination with percutaneous thermal ablation in patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases (CRLM). The study included 452 patients undergoing 2654 repetitive cTACE treatments of CRLM. 233 patients were treated palliatively using only cTACE, whereas 219 patients were treated with cTACE in a neoadjuvant intend with subsequent thermal ablation (either microwave ablation or laser-induced thermotherapy). The chemotherapeutics agents used, in either single-, double-, or triple-combinations, included MitomycinC, Gemcitabine, Irinotecan, and Cisplatin. Several factors were analysed to determine their prognostic value in terms of OS and PFS. Palliative use of cTACE resulted in a median OS and PFS of 12.6 and 5.9 months, whereas the neoadjuvant use of cTACE showed a median OS and PFS of 25.8 and 10.8 months. The differences in OS and PFS between the two groups were statistically significant (p